Business Context and Reporting Period
Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and hyaluronic acid (HA) manufacturing. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company recently transitioned from a fiscal year ending in May to a calendar year ending December 31. Consequently, comparative data is presented against the three-month period ended February 23, 2025, rather than the prior calendar quarter.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 (Comparable) |
|---|---|---|
| Total Revenues | $23.2 million | $35.2 million |
| Gross Profit | $4.5 million | $9.8 million |
| Gross Margin | 19.2% | 28.0% |
| Net Loss | $(15.0) million | $(14.8) million |
| Loss Per Share (Basic/Diluted) | $(0.43) | $(0.42) |
| Operating Cash Flow | $4.7 million | $1.2 million |
| Cash and Equivalents | $20.8 million | $5.4 million |
| Total Debt (Principal) | $200.1 million | $195.8 million |
| Consolidated Liquidity | $38.1 million | N/A |
Note: Consolidated liquidity includes cash and cash equivalents ($20.8M) plus available borrowing capacity under the Revolving Credit Facility ($17.3M).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 34% ($12.0 million) primarily due to a 48% drop in HA manufacturing revenue ($6.9 million) and a 24% drop in CDMO revenue ($5.0 million). The HA decline was driven by the absence of prior-period supply chain demand, while CDMO declines were due to lower sales volumes and the completion of discrete development projects.
- Gross Margin Compression: Gross profit fell 55% to $4.5 million, with the margin contracting from 28.0% to 19.2%. This was largely attributed to decreased sales volume and manufacturing absorption in the HA segment.
- Operating Expenses: Total operating expenses decreased 52% to $9.1 million. This significant reduction was driven by the absence of a $6.9 million loss on the sale of assets recorded in the prior period, alongside reductions in R&D and SG&A expenses.
- Interest and Derivative Costs: Net interest expense increased 32% to $7.2 million due to accumulating interest paid-in-kind (PIK) on the Alcon term loan. Additionally, the change in fair value of the debt derivative liability increased to a $3.2 million expense, driven by a higher discount rate reflecting a decline in the Company's synthetic credit rating.
- Cash Flow Improvement: Operating cash flow improved significantly to $4.7 million, primarily due to a $5.5 million positive change in working capital, specifically from receivable collections.
Outlook, Risks, and Contingencies
- Liquidity and Debt: The Company maintains approximately $194.2 million in total indebtedness with Alcon, including a Term Loan with an effective annual interest rate of 20.9%. The Company is currently in compliance with all financial covenants, including a minimum liquidity requirement of $4.0 million.
- Preferred Stock Redemption: Holders of Series A Redeemable Convertible Preferred Stock may require redemption beginning June 29, 2026. The aggregate liquidation preference is approximately $49.3 million. Management estimates internally generated cash will not be sufficient to fund significant redemptions, potentially requiring additional financing.
- Legal Proceedings:
- Class Action: A settlement agreement in principle was reached regarding a securities class action, subject to court approval. The Company expects this to be covered by insurance with no material loss.
- Investor Dispute: A lawsuit by 22NW Fund remains partially active regarding alleged breaches of representations, though claims for registration delay fees were dismissed as moot after payment.
- SEC Investigation: The SEC concluded its investigation regarding a financial statement restatement with no action taken against the Company.
- Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of March 31, 2026, due to a material weakness in IT general controls related to its legacy ERP system. Remediation is underway following the launch of a new ERP system in January 2026.
Investor Verification Checklist
- Preferred Stock Redemption Risk: Verify the Company's ability to raise capital or refinance debt to meet the potential $49.3 million redemption obligation for Series A Preferred Stock starting June 29, 2026.
- Debt Service Costs: Monitor the impact of the 20.9% effective interest rate on the Alcon Term Loan and the volatility of the debt derivative liability on future earnings.
- Revenue Concentration: Confirm the stability of the relationship with Alcon, which accounted for 39% of Q1 2026 revenue and is also the primary lender.
- Internal Control Remediation: Track the progress of the new ERP system implementation and the timeline for declaring the material weakness in internal controls as remediated.
- Working Capital Trends: Assess whether the strong receivable collections in Q1 2026 are sustainable or a one-time event, given the revenue decline.